Avant Technologies Signs Joint Venture to Advance Cell-Based Diabetes Treatment
The Joint Venture will now pursue a Research Collaboration Agreement (RCA) to advance a proprietary differentiation process that efficiently converts stem cells into insulin-producing and regulating cells, forming the core of its therapy for type 1 and some insulin-dependent type 2 diabetes.
This alliance focuses on researching, developing, producing, and marketing sophisticated diabetes treatments that employ encapsulated stem cells-differentiated before, during, or after encapsulation. By integrating potential RCA-derived stem cell expertise with SGAustria’s encapsulation platform, the partners seek to deliver safe, potent, and scalable solutions for type 1 and some insulin-dependent type 2 diabetes patients globally.
The partnership will lead to the creation of Insulinova, Inc., a
Avant’s Chief Executive Officer (CEO), Chris Winter, commenting on the partnership, “We’re thrilled to join forces with SGAustria in this game-changing Joint Venture. Merging our capital and forward-thinking strategy with their advanced biotech innovations, we’re setting the stage for revolutionary diabetes therapies that have the potential to transform countless lives. This milestone represents a defining step for Avant as we commit to the advancement of regenerative healthcare.”
Key Contributions to the Joint Venture:
- SGAustria brings to the Joint Venture its proprietary, clinically proven cell-encapsulation technology, designed to protect, isolate, store, and transport living cells. Backed by over 50 peer-reviewed publications and contracts with leading global biotechnology companies, SGAustria’s expertise in cell biology and GMP-grade manufacturing will support the development and commercialization of these treatments.
-
Avant Technologies will provide initial funding over the next eight months to achieve established criteria relevant for an efficient, sustainable, and reproducible treatment of diabetes. Additionally, Avant will leverage its resources to secure further funding to advance the Joint Venture toward a potential Phase 1 clinical trial in
the United States or equivalent territory.
“SGAustria’s encapsulation platform holds tremendous promise for reshaping cell therapies, and this Joint Venture stands as proof of that potential,” stated Brian Salmons, CEO of SGAustria. “Teaming up with Avant and a prospective RCA partner allows us to leverage our combined capabilities to deliver cutting-edge, reliable diabetes treatments, supported by our established proficiency in GMP production and cellular science.”
About Avant Technologies Inc.
Avant Technologies Inc. is an emerging
About SGAustria Pte. Ltd.
SGAustria, based in
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251104188384/en/
Avant Technologies Inc.
info@avanttechnologies.com
Source: Avant Technologies Inc.
